For Parkinson Therapy IPX203, Amneal has announced the complete response resubmission.

Published Date: 11 Feb 2024

Results from the phase 3 RISE-PD trial, in which treated patients demonstrated greater ON time than immediate-release CD/LD, supported the new drug application for IPX203, a novel oral formulation of carbidopa/levodopa.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Geriatric Assessment, QoL Correlate With OS in Older Patients with Pancreatic Cancer

2.

Higher Binge Drinking Rates Linked to New Cannabis Laws.

3.

Cancer Patients Who Completed Medication Survey Received More Help From Pharmacists

4.

Ketamine plus psychotherapy for "excellent" PTSD

5.

No Seed Oil-Colon Cancer Link; Avoiding Prostate Biopsy; Top Cancer Advances


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot